Online Only Articles

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study

Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;Seattle Genetics, WA
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO
Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD
Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD
Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD
Lymphoma Division, John Theurer Cancer Hackensack University Medical Center, Hackensack, NJ, USA
Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Vol. 104 No. 2 (2019): February, 2019 https://doi.org/10.3324/haematol.2018.199844